A couple of heavyweight European drug makers are revamping their R&D teams in an effor to...

|By:, SA News Editor

A couple of heavyweight European drug makers are revamping their R&D teams in an effor to boost lagging output. AstraZeneca (AZN -1.2%) replaces its head of R&D and will split the top R&D job into three new positions: small molecule drugs, biological drugs and late-stage development - which includes the oversight of large clinical trials. Roche (RHHBY.PK -0.2%) meanwhile, appoints an American scientist to run it's Basel-based drug research unit, which trails it's California-based Genentech unit in new drug discoveries.